Elo Mutual Pension Insurance Co Sells 949 Shares of Kenvue Inc. (NYSE:KVUE)

Elo Mutual Pension Insurance Co lessened its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 198,390 shares of the company’s stock after selling 949 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Kenvue were worth $4,236,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of KVUE. Grove Bank & Trust boosted its position in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. bought a new stake in Kenvue in the 4th quarter valued at approximately $29,000. SRS Capital Advisors Inc. boosted its position in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its stake in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Evercore ISI started coverage on Kenvue in a report on Monday. They set an “in-line” rating and a $25.00 target price on the stock. Canaccord Genuity Group raised their price target on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $24.00.

Kenvue Price Performance

NYSE:KVUE opened at $23.52 on Friday. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company has a market cap of $44.95 billion, a P/E ratio of 44.38, a P/E/G ratio of 2.62 and a beta of 1.25. The firm’s fifty day moving average price is $22.27 and its two-hundred day moving average price is $22.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.49%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.